novo nordisk fda semaglutide wins approval for higher-dose Ozempic for adults with type 2 diabetes In a new study, Ozempic-maker

Pooled semaglutide data showed a significant reduction of 32% in risk of stroke compared with placebo

Research published since the STEP trials shows that adequate protein intake (1.0 to 1.6 grams per kilogram of body weight daily) combined with resistance training two to three times per week can significantly reduce lean mass loss, potentially lowering it to 20 to 25 percent of total weight lost

as described previously.16 The glycaemic target is to be determined for each patient based on the recommendations of the Japan Diabetes Society.17 Serum and urine metabolic parameters, clinic BP, pulse rate, body weight and abdominal circumference will be measured at each study visit

Novo Nordisk conducted pharmacokinetic studies during semaglutide development that compared absorption across injection sites

The Global Market Landscape for GLP-1 Medications GLP-1 therapies are rapidly expanding in Europe, the Asia-Pacific region, including India and China, driven by rising obesity and supportive healthcare initiatives